background
goal
studi
character
viral
load
factor
affect
viral
clearanc
person
sever
influenza
method
prospect
observ
studi
involv
consecut
adult
hospit
influenza
nasal
throat
swab
collect
present
daili
week
symptom
onset
realtim
reversetranscriptas
polymeras
chain
reaction
determin
viral
rna
concentr
viru
isol
perform
viral
rna
concentr
analyz
use
multipl
linear
logist
regress
mixedeffect
model
result
one
hundr
fortyseven
inpati
influenza
infect
studi
mean
age
standard
deviat
year
viral
rna
concentr
present
posit
correl
symptom
score
significantli
higher
among
timematch
outpati
control
subject
patient
major
comorbid
high
viral
rna
concentr
even
present
day
symptom
onset
mean
standard
deviat
vs
log
copiesml
b
confid
interv
p
p
viral
rna
concentr
demonstr
nonlinear
decreas
time
oseltamivirtr
untreat
patient
rna
detect
week
symptom
onset
oseltamivir
start
symptom
day
independ
associ
acceler
decreas
viral
rna
concentr
mean
b
standard
error
log
copiesml
patient
treat
day
day
respect
viral
rna
clearanc
week
odd
ratio
confid
interv
patient
treat
day
day
respect
convers
major
comorbid
system
corticosteroid
use
asthma
chronic
obstruct
pulmonari
diseas
exacerb
associ
slower
viral
clearanc
viral
rna
clearanc
associ
shorter
hospit
stay
vs
among
younger
previous
healthi
individu
outpati
set
viral
replic
pattern
efficaci
antivir
drug
adequ
studi
sever
influenza
studi
undertaken
character
viral
load
chang
larg
hospit
cohort
use
realtim
reversetranscript
polymeras
chain
reaction
rtpcr
assay
examin
factor
influenc
rate
viral
rna
decreas
clearanc
patient
prospect
observ
studi
patient
age
year
laboratoryconfirm
influenza
admit
consecut
princ
wale
hospit
hong
kong
januari
decemb
conduct
princ
wale
hospit
teach
hospit
serv
urban
popul
million
person
eastern
new
territori
region
hong
kong
oper
hospit
author
key
provid
acut
medic
servic
hong
kong
patient
hospit
influenza
diagnos
treat
accord
standard
protocol
brief
adult
patient
present
acut
febril
respiratori
ill
requir
hospit
admit
design
medic
ward
droplet
precaut
implement
patient
admit
hospit
develop
potenti
seriou
medic
condit
exacerb
underli
chronic
ill
sever
symptom
consid
unmanag
home
nasopharyng
aspir
perform
immunofluoresc
assay
detect
influenza
b
infect
accord
local
guidelin
patient
hospit
confirm
influenza
within
day
symptom
onset
receiv
standard
cours
oseltamivir
treatment
mg
twice
daili
day
howev
patient
present
later
decis
regard
antivir
treatment
made
physician
patient
otherwis
treat
discharg
accord
usual
clinic
practic
consecut
patient
recruit
studi
diagnosi
influenza
b
establish
nasopharyng
aspirationimmunofluoresc
assay
obtain
written
inform
consent
separ
nasal
throat
swab
collect
combin
viral
load
test
design
research
nurs
respons
collect
swab
standard
techniqu
specimen
collect
start
day
recruit
continu
daili
week
symptom
onset
patient
discharg
earli
specimen
collect
arrang
outpati
basi
swab
sent
viral
rna
concentr
determin
viru
isol
patient
present
emerg
depart
princ
wale
hospit
influenza
requir
hospit
recruit
control
subject
similarli
nasopharyng
aspir
nasal
throat
swab
obtain
present
serial
sampl
perform
patient
posit
nasopharyng
aspirationimmunofluoresc
assay
result
age
year
neither
document
medic
comorbid
evid
influenzarel
complic
includ
comparison
none
receiv
antivir
treatment
clinic
data
record
prospect
standard
instrument
includ
demograph
characterist
medic
comorbid
influenza
vaccin
statu
symptomfev
onset
time
defin
symptom
day
symptom
sever
score
record
scale
regard
nasal
obstruct
sore
throat
cough
myalgia
fatigu
headach
feverish
influenzarel
complic
detail
antivir
treatment
receiv
system
corticosteroid
use
treatment
exacerb
chronic
obstruct
pulmonari
diseas
asthma
clinic
outcom
major
comorbid
defin
presenc
follow
chronic
system
medic
condit
congest
heart
failur
cerebrovascular
neoplast
chronic
liver
renal
diseas
use
immunosuppress
associ
impair
host
immun
defens
ethic
approv
obtain
institut
review
board
hospit
author
hong
kong
chines
univers
hong
kong
studi
support
govern
research
grant
nasopharyng
aspir
subject
immunofluoresc
stain
viru
isol
subsequ
viru
subtyp
describ
elsewher
influenza
viru
isol
differenti
subtyp
nation
influenza
refer
laboratori
centr
health
protect
hong
kong
nasal
throat
swab
put
togeth
prepar
bottl
contain
fix
amount
ml
viral
transport
medium
sampl
aliquot
equal
part
one
portion
use
influenza
viru
isol
madindarbi
canin
kidney
cell
describ
appendix
appear
onlin
version
journal
elsewher
anoth
portion
store
subsequ
viral
rna
concentr
determin
virolog
investig
perform
biosafeti
level
ii
laboratori
viral
rna
concentr
assay
influenza
rna
concentr
nasal
throat
swab
sampl
determin
use
realtim
quantit
rtpcr
method
describ
appendix
appear
onlin
version
note
patient
posit
nasopharyng
aspir
immunofluoresc
assay
result
influenza
viru
isol
patient
remain
patient
posit
result
immunofluoresc
assay
reversetranscriptas
polymeras
chain
reaction
subtyp
perform
isol
confirm
viru
patient
provid
serial
sampl
remaind
return
subsequ
sampl
discharg
death
n
p
twentyf
inpati
confirm
influenza
infect
refus
conn
p
sent
studi
medic
comorbid
major
classif
base
pneumonia
port
sever
index
score
system
major
system
comorbid
includ
congest
heart
failur
cerebrovascular
neoplast
chronic
liver
renal
diseas
use
immunosuppress
patient
might
also
coexist
ill
comorbid
refer
presenc
major
system
signific
medic
ill
includ
mainli
chronic
lung
diseas
asthma
chronic
obstruct
pulmonari
diseas
bronchiectasi
diabet
ischem
heart
diseas
neun
p
rolog
diseas
patient
cohort
receiv
immunosuppress
journal
elsewher
viral
rna
extract
result
complementari
dna
product
cdna
use
immedi
realtim
pcr
primer
design
detect
influenza
human
subtyp
includ
circul
b
viru
rna
target
mgene
influenza
viru
aand
bspecif
fluorogen
probe
appendix
appear
onlin
version
journal
design
anneal
intern
sequenc
amplifi
region
realtim
pcr
reaction
carri
use
stepon
realtim
pcr
machin
appli
biosystem
plasmid
contain
known
copi
number
amplif
target
includ
realtim
pcr
assay
gener
standard
curv
quantif
test
sampl
lower
detect
limit
influenza
realtim
pcr
assay
copiesml
lower
limit
detect
copiesml
influenza
b
realtim
pcr
assay
statist
analysi
influenza
viral
rna
concentr
express
copiesml
log
transform
statist
analys
student
mannwhitney
u
x
test
use
univari
comparison
appropri
spearman
rank
correl
coeffici
use
assess
correl
viral
concentr
clinic
variabl
variabl
p
valu
univari
analys
enter
multipl
linear
regress
model
backward
identifi
independ
factor
affect
initi
viral
concentr
similarli
signific
variabl
enter
backward
p
stepwis
logist
regress
model
determin
independ
factor
associ
viral
clearanc
ie
undetect
viral
rna
detect
limit
rtpcr
assay
week
symptom
onset
adjust
odd
ratio
confid
interv
ci
calcul
explanatori
variabl
multivari
cox
proport
hazard
model
analysi
use
determin
independ
factor
associ
hospit
discharg
adjust
hazard
ratio
indic
higher
chanc
discharg
hospit
analys
p
valu
consid
indic
statist
signific
probabl
statist
analysi
perform
use
spss
softwar
version
spss
longitudin
data
mixedeffect
model
use
assess
associ
viral
concentr
chang
time
day
elaps
symptom
onset
age
sex
comorbid
initi
time
antivir
treatment
corticosteroid
use
mixedeffect
model
random
effect
model
take
account
hierarch
natur
data
withinand
betweensubject
heterogen
longitudin
data
model
allow
measur
made
unequ
interv
vari
number
measur
ie
subject
may
sever
measur
model
fit
method
restrict
iter
gener
leastsquar
algorithm
mln
window
softwar
packag
version
institut
educ
univers
london
likelihood
ratio
test
use
assess
statist
signific
estim
level
patient
descript
one
hundr
fortyseven
patient
influenza
includ
tabl
avail
viru
isol
confirm
subtyp
pre
thirtyseven
patient
receiv
antivir
treatment
receiv
diagnosi
symptom
day
initi
viral
concentr
measur
obtain
symptom
day
case
median
iqr
serial
measur
obtain
patient
patient
initi
specimen
obtain
immedi
treatment
remaind
initi
specimen
obtain
soon
treatment
initi
ie
dose
oseltamivir
analys
initi
viral
concentr
initi
viral
concentr
among
hospit
patient
shown
n
p
correl
posit
simultan
symptom
score
spearman
r
initi
pretreat
p
p
viral
concentr
also
compar
hospit
patient
influenza
timematch
outpati
control
present
within
day
ill
onset
outpati
year
age
underli
comorbid
none
receiv
antivir
treatment
found
mean
viral
concentr
among
hospit
patient
n
p
higher
among
outpati
n
p
log
copiesml
vs
log
copiesml
p
p
factor
affect
viral
load
start
treatment
shown
tabl
patient
major
system
comorbid
higher
initi
viral
concentr
among
patient
present
beyond
day
symptom
onset
viral
concentr
also
found
significantli
higher
major
comorbid
without
vs
log
copiesml
figur
shown
inp
p
note
age
sex
adjust
model
patient
initi
specimen
taken
immedi
treatment
start
antivir
initi
patient
initi
specimen
taken
dose
oseltamivir
treatment
receiv
antivir
initi
ye
se
standard
error
ci
confid
interv
final
multivari
model
includ
initi
viral
concentr
measur
presenc
major
con
p
morbid
longer
time
laps
symptom
onset
antivir
treatment
initi
present
found
independ
factor
affect
viral
concentr
tabl
viral
concentr
n
p
show
nonlinear
decreas
time
linear
p
quadrat
trend
likelihood
ratio
test
presenc
major
comorbid
mean
b
se
likep
p
lihoodratio
test
system
corticosteroid
use
acut
exacerb
asthma
chronic
obstruct
pulmonari
diseas
mean
b
se
slow
viral
concentrap
p
tion
decreas
wherea
antivir
treatment
start
symptom
day
mean
b
se
symptom
p
p
day
mean
b
se
associ
p
p
acceler
viral
concentr
decreas
compar
treatment
final
model
figur
interact
effect
found
variabl
durat
viral
shed
prolong
viral
rna
detect
observ
among
hospit
patient
influenza
overal
symptom
day
patient
respect
detect
influenza
viru
rna
rtpcr
tabl
among
patient
receiv
antivir
treatment
detect
rna
day
day
respect
proport
even
higher
among
major
comorbid
advanc
age
major
comorbid
system
corticosteroid
administr
significantli
associ
prolong
viral
rna
detect
wherea
antivir
treatment
start
symptom
day
significantli
associ
shorten
durat
viral
rna
detect
rna
detect
week
vs
p
p
tabl
shorter
time
discharg
hospit
associ
undetect
viral
rna
day
median
length
stay
vs
day
day
median
p
p
length
stay
day
vs
day
coxp
p
proport
hazard
model
undetect
viral
rna
level
within
day
symptom
onset
independ
associ
hospit
discharg
adjust
hazard
ratio
ci
adjust
age
comorbid
p
p
presenc
complic
result
viru
isol
also
shown
tabl
among
untreat
patient
remain
cultur
posit
symptom
day
day
respect
among
patient
comorbid
proport
even
higher
respect
antivir
treatment
significantli
associ
lower
rate
posit
cultur
cultur
posit
day
vs
cultur
posit
day
vs
p
p
reduct
observ
among
pap
p
tient
comorbid
cultur
posit
day
vs
p
p
total
patient
receiv
diagnosi
influenza
b
studi
period
influenza
patient
co
explan
clinic
variabl
reversetranscriptas
polymeras
chain
reaction
rtpcr
viru
isol
perform
nasal
throat
swab
sampl
total
patient
viral
shed
data
avail
week
symptom
onset
includ
analysi
consid
patient
major
comorbid
persist
viral
rna
detect
day
note
receiv
antivir
treatment
treatment
initi
day
treatment
initi
day
respect
x
persist
viru
isol
day
observ
p
p
respect
x
similar
studi
rate
posit
result
p
p
cultur
note
lower
rtpcr
reduc
viral
load
may
affect
cultur
posit
cultureposit
nasal
throat
swab
specimen
viral
rna
success
amplifi
viral
concentr
measur
morbid
higher
viral
concentr
present
vs
log
copiesml
multipl
p
p
linear
regress
b
se
ci
result
see
appendix
b
p
p
appear
onlin
version
journal
nearli
patient
influenza
b
detect
level
viru
rtpcr
week
ill
remain
cultur
posit
symptom
day
tabl
notabl
influenza
b
specimen
rtpcr
valu
copiesml
see
method
mixedeffect
model
analysi
perform
small
sampl
size
use
multipl
logist
regress
model
factor
associ
viral
clearanc
defin
neg
result
viral
rna
detect
day
analyz
influenza
b
infect
tabl
found
antivir
treatment
start
symptom
day
independ
associ
earli
viral
clearanc
wherea
influenza
b
infect
advanc
age
presenc
major
comorbid
system
corticosteroid
administr
factor
associ
persist
viral
rna
detect
similar
factor
identifi
affect
persist
viru
isol
symptom
day
day
appendix
c
appear
onlin
version
journal
antivir
treatment
start
symptom
day
associ
shorter
period
viru
isol
wherea
influenza
b
infect
comorbid
corticosteroid
administr
associ
longer
durat
persist
viru
isol
advanc
age
presenc
comorbid
known
associ
prolong
ill
poor
outcom
patient
hospit
influenza
infect
studi
demonstr
patient
may
higher
initi
viral
load
activ
viral
replic
tend
continu
beyond
first
day
ill
contrast
healthier
individu
consist
recent
report
prolong
viral
rna
detect
day
ill
onset
observ
among
patient
associ
longer
durat
ill
hospit
find
suggest
prolong
viral
replic
may
common
previous
recogn
patient
hospit
influenza
limit
immunosuppress
patient
hematolog
malign
found
presenc
comorbid
concomit
system
corticosteroid
administr
may
slow
viral
clearanc
wherea
oseltamivir
treatment
start
within
first
day
ill
may
enhanc
viral
clearanc
patient
oseltamivir
start
reduc
viral
load
day
treatment
howev
viral
level
decreas
influenc
time
initi
best
effect
lowest
viral
load
observ
treatment
initi
day
symptom
onset
also
differ
influenza
viru
type
may
show
differ
degre
respons
oseltamivir
sever
import
implic
first
earli
diagnosi
therapeut
intervent
sever
influenza
emphas
patient
encourag
present
soon
symptom
develop
despit
vaccin
statu
prompt
laboratori
diagnost
test
may
use
guid
treatment
rtpcr
avail
test
choic
high
sensit
specif
sensit
test
unavail
empir
antivir
therapi
may
consid
especi
season
peak
high
likelihood
influenza
patient
serious
ill
second
extend
therapeut
time
window
initi
antivir
therapi
may
consid
previou
clinic
trial
involv
otherwis
healthi
younger
nonhospit
patient
suggest
produc
clinic
benefit
antivir
treatment
initi
within
h
symptom
initi
activ
viral
replic
larg
subsid
beyond
time
determin
basi
viral
cultur
howev
among
older
patient
comorbid
present
h
particularli
associ
sever
persist
symptom
viral
load
may
remain
high
cultur
posit
recent
observ
studi
suggest
antivir
treatment
start
within
day
ill
onset
might
reduc
mortal
among
adult
patient
hospit
influenza
studi
antivir
treatment
start
within
day
ill
observ
enhanc
viral
load
decreas
clearanc
compar
treatment
adjust
confound
variabl
viral
clearanc
correl
symptom
resolut
may
associ
shorten
durat
hospit
random
control
trial
necessari
clarifi
clinic
benefit
delay
therapi
studi
viral
kinet
provid
use
inform
plan
eg
therapi
guid
viral
load
instead
time
symptom
onset
third
stringent
approach
infect
control
may
necessari
avoid
nosocomi
transmiss
hospit
patient
may
high
viral
load
long
durat
viral
shed
detect
rtpcr
cultur
method
measur
includ
strict
droplet
precaut
prefer
isol
extend
period
time
day
especi
patient
without
antivir
treatment
addit
aerosolgener
procedur
devic
use
caution
cellmedi
inmmun
respons
import
control
influenza
infect
use
system
corticosteroid
treat
concomit
medic
condit
sever
influenza
infect
shown
associ
slow
viral
decreas
clearanc
adjust
confound
corticosteroid
observ
slow
viral
clearanc
seriou
respiratori
viral
infect
respiratori
syncyti
viru
sever
acut
respiratori
syndromeassoci
coronaviru
infect
howev
clinic
signific
unknown
impact
cours
diseas
requir
investig
control
studi
vitro
data
suggest
differ
influenza
virus
influenza
b
may
differ
suscept
toward
neuraminidas
inhibitor
consist
recent
report
influenza
b
shown
slower
virolog
respons
oseltamivir
thu
altern
treatment
regimen
sever
influenza
b
infect
higher
oseltamivir
dosag
anoth
neuraminidaseinhibitor
deserv
clinic
evalu
studi
limit
observ
design
conduct
singl
center
patient
diagnos
within
day
symptom
onset
receiv
treatment
formal
recommend
regard
treatment
patient
present
later
howev
provid
bia
may
explain
find
like
sicker
patient
ongo
symptom
reflect
activ
viral
replic
prescrib
antivir
treatment
despit
later
present
wherea
patient
subsid
symptom
left
untreat
also
viru
concentr
upper
respiratori
tract
assay
nasal
throat
swab
may
precis
reflect
viru
replic
level
lower
respiratori
tract
although
approach
use
success
provid
semiquantit
estim
viru
burden
studi
natur
infect
similar
studi
observ
lower
posit
rate
viru
cultur
compar
rtpcr
assay
although
rtpcr
could
detect
nonviabl
viru
also
possibl
cultur
method
insensit
detect
lower
level
viru
excret
treatment
natur
defens
see
appendix
appear
onlin
version
journal
result
fals
neg
viru
inactiv
vitro
implic
infecti
would
requir
studi
nonetheless
still
observ
high
proport
untreat
patient
persist
viru
isol
beyond
day
ill
strengthen
conclus
basi
find
area
research
regard
manag
patient
hospit
influenza
includ
clinic
trial
delay
antivir
therapi
compromis
serious
ill
patient
use
higherdos
regimen
eg
mg
oseltamivir
twice
daili
prolong
cours
treatment
day
risk
emerg
antivir
resist
role
rapid
diagnost
test
differ
clinic
set
test
perform
affect
viral
load
specimen
type
adequaci
current
recommend
infect
control
measur
viral
kinet
influenza
viru
subtyp
eg
inform
import
influenza
pandem
prepared
conclus
hospit
adult
patient
influenza
may
activ
prolong
viral
replic
weaken
host
defens
slow
viral
clearanc
wherea
antivir
treatment
within
first
day
ill
enhanc
viral
clearanc
aggress
manag
infect
control
approach
appear
warrant
patient
